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Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoat-
tractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) 
by two research groups. We investigated the usefulness of CCL11 in diagnosing 
prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa.
Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 
44 men with PCa, and 45 control men attending an outpatient health-screening 
clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure 
CCL11.
Results: CCL11 concentrations were significantly higher in men with BPH and PCa 
than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, 
a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed 
that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) 
for BPH and PCa, respectively, compared with normal men.
Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH 
and PCa.
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INTRODUCTION
Eotaxin-1, also known as CC-chemokine ligand 11 (CCL11), 
is a protein expressed in various organs, such as the heart, 
central nervous system, and cerebrospinal fluid. Moreover, 
it is involved in immunoregulatory and inflammatory pro-
cesses and acts as a selective eosinophil chemo-attractant [1].
Chemokines are a large family of structurally homologous 
cytokines that are secreted by a variety of cells, including 
structural cells and leukocytes of the immune system. They 
bind to specific 7-transmembrane G protein-coupled recep-
tors, initiating a variety of downstream signals, notably ones 
that modulate polymerization of the actin cytoskeleton, ulti-
mately driving cellular motility. Excessive or inappropriate 
release of chemokines is observed in many inflammatory 
diseases [2].
Agarwal et al. [3] and Heidegger et al. [4] have both 
reported that serum CCL11 may be a new diagnostic marker 
for prostate cancer (PCa). However, there were conflicting 
results; for PCa, one of them reported increased CCL11, 
while the other reported decreased CCL11. Such difference 
is likely due to different measurement methods. 
In order to examine the possibility of using CCL11 as 
a diagnostic marker for prostatic diseases, the CCL11 levels 
were measured by enzyme-linked immunosorbent assay 
(ELISA) in individuals with benign prostatic hyperplasia 
(BPH) and PCa and compared with the levels in normal 
men.
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Table 1. Patient demographic, clinical and CCL11 data
 No disease BPH PCa Disease (BPH or PCa)
Total number 45 139 44 183
Mean age (y) 39.1±1.26 64.0±0.07 73.3±0.18 66.2±0.06
PSA (ng/ml) 0.9±0.00 2.6±0.03 90.2±5.75 23.9±0.71
CCL11 (pg/ml) 57.6±8.24 72.9±3.15 80.0±4.91 74.6±3.64
TRUS (ml) - 39.3±0.13 52.2±0.98 41.9±0.14
All the data are expressed as means±standard errors except for total 
numbers. PSA differed significantly between the three group (Kruskal- 
Wallis test, p＜0.0001). Forty-four with prostate cancer included 8 
patients with Gleason scores (GS) ＜6, 17 patients with GS of 7 and 19 
patients with GS of 8 or more.
CCL11: CC-chemokine ligand 11, BPH: benign prostatic hyperplasia, 
PCa: prostate cancer, PSA: prostate-specific antigen, TRUS: transrectal 
ultrasonography.
MATERIALS AND METHODS
1. Patient Population and Specimen Collection
Between October 2013 and November 2014, a total of 
183 men undergoing treatment in the Department of Urology 
at Hanyang University Seoul Hospital and Guri Hospital 
were enrolled in this study. Among them, there were 139 
men with BPH (mean age, 64.0±0.07 years) and 44 men 
with PCa (mean age, 73.3±0.18 years). 
The inclusion criteria for BPH were as follows: (1) A 
score of 8 or more according to the International Prostate 
Symptom Scores; (2) ＜4 ng/ml of prostate-specific antigen 
(PSA); (3) ＞20 ml of prostate volume (measured by 
transrectal ultrasonography; TRUS); and (4) ＞4 ng/ml of 
PSA and no evidence of malignant tumor on TRUS biopsy. 
Moreover, PCa patients were only selected if they had 
undergone a radiologic evaluation to determine their TNM 
clinical stage. A radiologic evaluation was carried out via 
chest computed tomography (CT), abdominal CT, prostate 
magnetic resonance imaging, and whole body bone scan.
The sera were obtained from 139 patients with BPH, 44 
with PCa, and 45 male volunteers (mean age, 39.1±1.26 
years) who visited Hanyang University International Hospital 
Health Promotion Center without any history of prostatic 
disease. Blood samples of 7 ml were collected, and plasma 
was stored at -70oC. 
This study was approved by the local Institutional Review 
Board of Hanyang University, and written informed consent 
was obtained from all participants (IRB no. HYUH 
2013-04-028-006). 
2. CCL11 Measurement
The levels of CCL11 were determined with a human CCL11 
ELISA kit (R&D Systems, Minneapolis, MN, USA) in 
accordance with the manufacturer's instructions. For the 
ELISA experiments, 96-well ELISA plates were coated with 
5 g/ml of diluted capture antibody (2 g/ml) and incubated 
overnight at room temperature. The plates were washed 
thrice with phosphate-buffered saline (PBS)-Tween 20 
(0.05% Tween 20 in PBS [pH 7.0]) followed by the addition 
of 200 l/well of blocking buffer (reagent diluent). After 
incubation at room temperature for 1 h, the plates were 
again washed 3× with PBS-Tween 20, and 80 l of serum 
was added to each well. After incubation for 2 h at room 
temperature, the plates were washed thirce with PBS-Tween 
20. Following the incubation with 100 l/well of detection 
antibody (0.2 g/ml) for 2 h at room temperature, the 
plates were washed 3× with PBS-Tween 20. Streptavidin- 
HRP (1:200) was added, and the plates were incubated 
at room temperature for 20 min and washed 3× with 
PBS-Tween 20. The color was developed by adding 100 
l/well of substrate solution (TMB Microwell Peroxidase 
Substrate System; KPL, Gaithersburg, MD, USA) at room 
temperature for 20 min. The absorbance was measured 
with an ELISA reader (Bio-Rad, Hercules, CA, USA) at 450 
nm after a 20 min incubation with stop solution (2.5 M 
H2SO4).
3. Statistical Analysis
IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, 
USA) was used for statistical analysis. Differences between 
the two groups (no disease vs. prostate disease) were 
analyzed using a Mann-Whitney U test. The differences 
between the three groups (no disease, BPH, PCa) were 
analyzed using a Kruskal-Wallis test. The correlation 
between PSA and CCL11 were analyzed using a Pearson 
correlation test. The p-values of less than 0.05 were set 
to be statistically significant. Receiver operator characteristic 
(ROC) analyses were performed to examine the sensitivity 
and specificity of CCL11 as a predictor of prostate diseases 
and to calculate the areas under the curves (AUCs) and 
confidence intervals. The data are presented as the means± 
SEMs, unless otherwise specified.
RESULTS
The study population consisted of 228 subjects; 45 
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Fig. 1. Serum CC-chemokine ligand 11 (CCL11) levels (pg/ml) in men 
without prostatic disease (normal) and patients with benign prostatic 
hyperplasia (BPH) and prostate cancer (PCa). (A) CCL11 differed 
significantly between the three group (Kruskal-Wallis test, *p-value=0).
(B) CCL11 levels are significantly higher in prostatic disease (BPH or 
PCa) than in normal men (Mann-Whitney test, *p-value=0.001). (C) 
CCL11 levels in patients with prostate cancers with different Gleason 
scores (GS).
controls without prostatic disease (PSA＜1 ng/ml), 139 
patients with BPH, and 44 with PCa, including 8 patients 
with Gleason scores (GS) ＜6, 17 patients with GS of 7, 
and 19 patients with GS of 8 or more (Table 1).
We enquired if serum CCL11 levels were different 
between prostatic disease (PCa and BPH) patients and 
individuals without prostatic disease. The serum CCL11 
levels for men without prostatic disease averaged 57.6 
pg/ml, whereas those for men with BPH and PCa averaged 
72.9 and 80.0 pg/ml, respectively (Table 1, Fig. 1). The 
CCL11 levels were significantly higher in PCa patients 
(p=0.012) and in BPH patients (p=0.001) than in healthy 
participants (Fig. 1A); however, there was no significant 
difference between the BPH (72.9 pg/ml) and PCa (80.0 
pg/ml) levels (Fig. 1A, B). 
We also investigated if CCL11 is a predictor of PCa 
aggressiveness. Thus, we measured CCL11 in PCa patients 
with different GS, and found that the CCL11 levels in men 
with GS 6 and with GS 8 or higher were similar: 73.1 
pg/ml and 76 pg/ml, respectively. The level measured in 
patients with GS 7 scores was 94.4 pg/ml, which was actually 
higher than that measured in patients with GS 6 and GS 
8. Therefore, we conclude that CCL11 levels do not differ 
between individuals with low, intermediate, and high risks 
of PCa (Fig. 1C).
Moreover, we performed a ROC analysis of serum CCL11 
levels to test whether CCL11 might be a marker for 
distinguishing between prostatic tumors (BPH, PCa) and 
disease-free prostates. The areas under the ROC curves 
were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and 
PCa, respectively, compared with normal men (Fig. 2). 
Additionally, AUC was 0.659 for prostate disease compared 
with normal men. This suggests that CCL11 can distinguish 
between prostatic tumorous conditions (BPH, PCa) and 
normal individuals without prostatic disease. Three AUC 
levels were ranged from 0.6 to 0.7, which indicate poor 
accuracy. Further study is required to distinguish the 
methods between normal and prostate disease.
We note that the PSA levels differed significantly between 
the three groups (normal, BPH & PCa), but there was no 
correlation between CCL11 and serum PSA levels (by 
Pearson correlation). 
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Fig. 2. Receiver operating characteristic (ROC) curves for CC-chemokine
ligand 11 (CCL11). (A) ROC curves distinguishing between benign 
prostatic hyperplasia (BPH) and no disease. The optimal cutoff of the 
CCL11 levels for distinguishing BPH from control (no disease) was 
determined as 53.1955 using the ROC curve (sensitivity=0.691, 
1-specificity=0.422). Area under the curve (AUC) was 0.661, and 95%
confidence interval (CI) was 0.560-0.762, p=0.001. (B) ROC curve 
distinguishing between prostate cancer (PCa) and no disease. The 
optimal cutoff of the CCL11 levels for distinguishing PCa from control 
(no disease) was determined as 52.6195 using the ROC curve 
(sensitivity=0.659, 1-specificity=0.467). AUC was 0.654, and 95% CI
was 0.540-0.768, p=0.012. (C) ROC curve distinguishing between 
prostatic disease and no disease. The optimal cutoff of the CCL11 levels
for distinguishing prostatic diseases from no disease was determined as
53.1955 using the ROC curve (sensitivity=0.683, 1-specificity=0.422).
AUC was 0.659, and 95% CI was 0.562-0.757, p=0.001.
DISCUSSION
BPH, a condition involving the abnormal progressive 
proliferation of prostatic stromal tissue and the cause lower 
urinary tract syndrome, is common in elderly men [5,6]. 
PCa is the second leading cause of cancer deaths in many 
western countries and accounted for more than 28,000 
deaths in the United States in 2013 [7]. However, key 
questions remain about how best to diagnose this cancer.
Numerous pro-inflammatory cytokines play a major role 
in inflammatory disease and carcinogenesis.
Inflammation of the prostate, including activation of 
inflammatory cells and production of cytokines, appears 
to be an important causal factor in BPH and PCa [8,9]. 
Thus, various cytokines such as interleukin (IL)-8, IL-1, 
IL-6, tumor necrosis factor-, CXCL5, CXCL12 have been 
tried as biomarkers for prostatic diseases [10-12].
Very little is known regarding the potential role(s) of 
CCL11 in prostate pathology. CCL11 is known as a 
chemotactic factor that binds to the CCR3 receptor, activates 
the mitogen-activated protein kinase pathway, and stimulates 
cellular invasion by regulating the expression of matrix 
metalloproteinase-3 [13]. CCL11 has been proposed by two 
research groups to be a serum marker for PCa; Agarwal 
et al. [3] suggested that serum CCL11 may be a useful 
diagnostic tool to help distinguish between prostatic 
enlargement and PCa among men demonstrating low, but 
detectable, serum PSA value; Heidegger et al. [4] reported 
that CCL11 may serve as a diagnostic marker to distinguish 
between disease-free prostate condition and PCa. 
However, most PCa are first found during screening with 
a PSA blood test, alone or in combination with a digital 
rectal exam, followed by a diagnostic biopsy and potentially 
imaging if there is a suspicion of cancer spread. When 
PCa is diagnosed, PSA levels are used in tumor staging 
and for tracking cancer progression [14]. PSA screening is 
associated with a significant decline in prostate cancer- 
specific mortality in the US over the past two decades [15,16], 
although the recommendation by the United States Pre-
ventive Services Task Force does imply that low serum PSA 
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values alone do not reliably predict clinically significant 
prostate tumors. Therefore, there is a critical need to develop, 
validate, and determine the utility of other serum transcripts 
and protein markers as diagnostic markers for PCa [3].
 Several markers, including prostate-specific membrane 
antigen, hepsin, a-methylacyl-coenzyme A racemase, 
telomerase, serine protease TMPRSS2, d-catenin, and 
prostate-specific non-coding RNA called prostate cancer 
gene 3 (PCA3, formerly known as DD3), have been 
identified and tested to date; these markers, when used 
alone or in combination with serum PSA, have been 
determined to be variously useful as diagnostic or prognostic 
markers of PCa [17-20]. 
CCL11 is a ligand for the G-protein coupled receptor, CCR3, 
which is expressed on eosinophils, basophils, and Th2 helper 
T-cells [21-23]. In addition to its role as a chemo-attractant, 
CCL11 has been implicated in different eosinophilic 
inflammatory diseases, such as atopic dermatitis, allergic 
rhinitis, sinusitis, asthma, ulcerative colitis, and in several 
other gastrointestinal disorders, as well as in parasitic 
infections [24-28]. Moreover, the levels of serum or plasma 
CCL11 as diagnostic or prognostic cancer markers have 
been described in high-grade renal cell carcinomas, 
high-risk neuroblastoma, as well as in head and neck small 
cell carcinomas [29-31].
In this study, BPH and PCa showed a significantly increased 
CCL11 concentration than normal prostate. In addition, CCL11 
of PCa is higher than that of BPH, although there is not 
a significant difference between the two group. The CCL11 
levels do not differ between individuals with low, 
intermediate, and high risks of PCa classified by the GS.
However, the CCL11 plasma level was reported to increase 
with age in humans [32,33]. A limitation of our study is 
that the age of normal men (control group) without prostatic 
diseases is younger than that of prostatic diseases. The 
reason for this is that it is difficult to get a serum from 
prostatic diseases-free men of old age. CCL11 of the normal 
group showed lower levels than that of prostatic diseases, 
and the lower levels of CCL11 in normal men would be 
partially explained by young age. Further study is required 
to compare the CCL11 levels between prostatic tumor and 
control men of similar age to get a better understanding 
of using CCL11 as a biomarker for PCa. Taken together, 
this result suggested that CCL11 may be a supplementary 
diagnostic tool to differentiate between normal prostate 
and prostate tumor. 
CONCLUSIONS
CCL11 may be helpful in distinguishing between normal 
disease-free prostate and prostatic diseases, such as BPH 
and PCa.
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